SAC3D1 activates Wnt/β‑catenin signalling in hepatocellular carcinoma

Wang,Haitao; Shi,Xiufang

doi:10.3892/mmr.2022.12833

SAC3D1 activates Wnt/β‑catenin signalling in hepatocellular carcinoma

Authors:
- Haitao Wang
- Xiufang Shi
View Affiliations

Affiliations: Laboratory Center of Bozhou People's Hospital, The Bozhou Hospital Affiliated to Anhui Medical University, Bozhou, Anhui 236800, P.R. China
Published online on: August 24, 2022 https://doi.org/10.3892/mmr.2022.12833
Article Number: 317

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

β‑catenin accumulates in hepatocellular carcinoma (HCC); therefore, understanding the mechanism of Wnt/β‑catenin pathway activation is important for HCC therapy. SAC3 domain containing 1 (SAC3D1) is involved in numerous types of cancer, such as gastric cancer. To the best of our knowledge, however, the role of SAC3D1 in HCC has not yet been elucidated. Here, the expression of SAC3D in HCC was examined by quantitative PCR, western blotting and immunohistochemistry. The function of SAC3D1 in HCC were examined using Cell Counting Kit‑8 and anchorage‑independent growth assay. It was found that the levels of SAC3D1 mRNA and protein were upregulated in HCC. When SAC3D1 was overexpressed, the proliferation of HCC cells was promoted; when the expression of SAC3D1 was disrupted, HCC cell growth was inhibited. When the molecular mechanism was investigated using immunoprecipitation, it was found that SAC3D1 interacted with axin, inhibiting ubiquitination of β‑catenin and elevating protein levels of β‑catenin. In summary, the present study revealed the promoting function of SAC3D1 in the progression of HCC. SAC3D1 may be a promising target for HCC therapy.

View Figures

View References

1	Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J and Finn RS: Hepatocellular carcinoma. Nat Rev Dis Primers. 7:62021. View Article : Google Scholar : PubMed/NCBI
2	Altomonte J. Liver cancer, . Sensitizing hepatocellular carcinoma to oncolytic virus therapy. Nat Rev Gastroenterol Hepatol. 15:8–10. 2018. View Article : Google Scholar : PubMed/NCBI
3	Bruix J, da Fonseca LG and Reig M: Insights into the success and failure of systemic therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 16:617–630. 2019. View Article : Google Scholar : PubMed/NCBI
4	Schunk SJ, Floege J, Fliser D and Speer T: WNT-β-catenin signalling-a versatile player in kidney injury and repair. Nat Rev Nephrol. 17:172–184. 2021. View Article : Google Scholar : PubMed/NCBI
5	Moon RT, Kohn AD, De Ferrari GV and Kaykas A: WNT and β-catenin signalling: Diseases and therapies. Nat Rev Genet. 5:691–701. 2004. View Article : Google Scholar : PubMed/NCBI
6	Kypta RM and Waxman J: Wnt/β-catenin signalling in prostate cancer. Nat Rev Urol. 9:418–428. 2012. View Article : Google Scholar : PubMed/NCBI
7	Leavy O. Mucosal immunology, . β-catenin calms the gut. Nat Rev Immunol. 10:6822010. View Article : Google Scholar : PubMed/NCBI
8	Mosimann C, Hausmann G and Basler K: Beta-catenin hits chromatin: Regulation of Wnt target gene activation. Nat Rev Mol Cell Biol. 10:276–286. 2009. View Article : Google Scholar : PubMed/NCBI
9	Clevers H. Axin and hepatocellular carcinomas. Nat Genet. 24:206–208. 2000. View Article : Google Scholar : PubMed/NCBI
10	Ishizaki Y, Ikeda S, Fujimori M, Shimizu Y, Kurihara T, Itamoto T, Kikuchi A, Okajima M and Asahara T: Immunohistochemical analysis and mutational analyses of beta-catenin, Axin family and APC genes in hepatocellular carcinomas. Int J Oncol. 24:1077–1083. 2004.PubMed/NCBI
11	Tian W, Li J, Wang Z, Zhang T, Han Y, Liu Y, Chu W, Liu Y and Yang B: HYD-PEP06 suppresses hepatocellular carcinoma metastasis, epithelial-mesenchymal transition and cancer stem cell-like properties by inhibiting PI3K/AKT and WNT/β-catenin signaling activation. Acta Pharm Sin B. 11:1592–1606. 2021. View Article : Google Scholar : PubMed/NCBI
12	Huang Y, Sheng H, Xiao Y, Hu W, Zhang Z, Chen Y, Zhu Z, Wu D, Cao C and Sun J: Wnt/β-catenin inhibitor ICG-001 enhances the antitumor efficacy of radiotherapy by increasing radiation-induced DNA damage and improving tumor immune microenvironment in hepatocellular carcinoma. Radiother Oncol. 162:34–44. 2021. View Article : Google Scholar : PubMed/NCBI
13	Yu Y, Zhang L and Xu J: LncRNA BANCR promotes proliferation of hepatocellular carcinoma Huh-7 cells by activating Wnt/beta-catenin signaling pathway. Minerva Gastroenterol (Torino). Jun 11–2021.(Epub ahead of print). View Article : Google Scholar
14	Yang T, Xu R, Huo J, Wang B, Du X, Dai B, Zhu M, Zhan Y, Zhang D and Zhang Y: WWOX activation by toosendanin suppresses hepatocellular carcinoma metastasis through JAK2/Stat3 and Wnt/β-catenin signaling. Cancer Lett. 513:50–62. 2021. View Article : Google Scholar : PubMed/NCBI
15	Adebayo Michael AO, Ko S, Tao J, Moghe A, Yang H, Xu M, Russell JO, Pradhan-Sundd T, Liu S, Singh S, et al: Inhibiting glutamine-dependent mTORC1 activation ameliorates liver cancers driven by β-catenin mutations. Cell Metab. 29:1135–1150.e6. 2019. View Article : Google Scholar : PubMed/NCBI
16	Han ME, Kim JY, Kim GH, Park SY, Kim YH and Oh SO: SAC3D1: A novel prognostic marker in hepatocellular carcinoma. Sci Rep. 8:156082018. View Article : Google Scholar : PubMed/NCBI
17	Liu AG, Zhong JC, Chen G, He RQ, He YQ, Ma J, Yang LH, Wu XJ, Huang JT, Li JJ, et al: Upregulated expression of SAC3D1 is associated with progression in gastric cancer. Int J Oncol. 57:122–138. 2020.PubMed/NCBI
18	Nakajima H, Tamura T, Ito M, Shibata F, Kuroda K, Fukuchi Y, Watanabe N, Kitamura T, Ikeda Y and Handa M: SHD1 is a novel cytokine-inducible, negative feedback regulator of STAT5-dependent transcription. Blood. 113:1027–1036. 2009. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Guan CN, Chen XM, Lou HQ, Liao XH, Chen BY and Zhang PW: Clinical significance of axin and β-catenin protein expression in primary hepatocellular carcinomas. Asian Pac J Cancer Prev. 13:677–681. 2012. View Article : Google Scholar : PubMed/NCBI
21	Park JY, Park WS, Nam SW, Kim SY, Lee SH, Yoo NJ, Lee JY and Park CK: Mutations of beta-catenin and AXIN I genes are a late event in human hepatocellular carcinogenesis. Liver Int. 25:70–76. 2005. View Article : Google Scholar : PubMed/NCBI
22	Kitao A, Matsui O, Yoneda N, Kozaka K, Kobayashi S, Sanada J, Koda W, Minami T, Inoue D, Yoshida K, et al: Hepatocellular carcinoma with β-catenin mutation: Imaging and pathologic characteristics. Radiology. 275:708–717. 2015. View Article : Google Scholar : PubMed/NCBI
23	Yu J, Xie Y, Li M, Zhou F, Zhong Z, Liu Y, Wang F and Qi J: Association between SFRP promoter hypermethylation and different types of cancer: A systematic review and meta-analysis. Oncol Lett. 18:3481–3492. 2019.PubMed/NCBI
24	Xu C, Zeng XH, Wang L, Tao SQ, Wu QX, Zhu P, Deng GH and Wang YM: sFRP-4, a potential novel serum marker for chronic hepatitis B-related hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 14:164–170. 2015. View Article : Google Scholar : PubMed/NCBI
25	Bengochea A, de Souza MM, Lefrançois L, Le Roux E, Galy O, Chemin I, Kim M, Wands JR, Trepo C, Hainaut P, et al: Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma. Br J Cancer. 99:143–150. 2008. View Article : Google Scholar : PubMed/NCBI